avenciguat + empagliflozin

Avenciguat + empagliflozin is an investigational oral fixed-dose combination of two small molecules: avenciguat (a soluble guanylate cyclase [sGC] activator) and empagliflozin (a sodium-glucose co-transporter 2 [SGLT2] inhibitor). Avenciguat (also known as BI 685509) activates sGC to increase cyclic GMP production, attenuating the effects of oxidative stress and nitric oxide deficiency, which are implicated in diabetic vascular and fibrotic complications. Empagliflozin selectively inhibits SGLT2 in the kidney, promoting glucose excretion and improved glycemic control. The combination has been shown in preclinical and clinical studies to provide additive or synergistic benefits in slowing the progression of diabetic nephropathy and hepatic fibrosis compared to monotherapy. This combination is under investigation primarily for complications arising from type 2 diabetes, including diabetic kidney disease, liver cirrhosis, and nonalcoholic steatohepatitis (NASH)[1][3][5].

Other names

avenciguat and empagliflozin